Intracellular bioactivity of macrolides

Clinical Microbiology and Infection

Volumn 1, Issue SUPPL. 1, 1996, Pages

  Labro, Marie Thérèse ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Intracellular bioactivity; Macrolides; Phagolysosomes; Polymorphonuclear neutrophils

Indexed keywords

EID: 0002043633     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1996.tb00588.x     Document Type: Article

References (39)

1. Kirst HA. New macrolides: expanded horizons for an old class of antibiotics. J Antimicrob Chemother 1991; 28: 787-90.
2. Kirst HA, Sides BD. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother 1989; 33: 1419-22.
3. Moulder JW. Comparative biology of intracellular parasitism. Microbiol Rev 1985; 49: 298-337.
4. Labro MT. Intraphagocytic penetration of macrolides. In Bryskier AJ, Butzler JP, Neu HC, Tulkens PM, eds. Macrolides: chemistry, pharmacology and clinical uses. Paris: Arnette-Blackwell, 1993; 379-88.
5. Mtairag EM, Abdelghaffar H, Labro MTJ. Investigation of dirithromycin and erythromycylamine uptake by human neutrophil, in vitro. J Antimicrob Chemother 1994; 33: 523-6.
6. Mtairag EM, Abdelghaffar H, Douhet C, Labro MT. Role of extracellular calcium in in vitro uptake and intraphagocytic location of macrolides. Antimicrob Agents Chemother 1995; 39: 1676-82.
7. Fietta A, Boeri P, Colombo ML, Merlini C, Gialdroni-Grassi G. Bioactivity of flurithromycin and other macrolides against intracellular susceptible staphylococci. Chemotherapy 1993; 39: 48-54.
8. Scorneaux B, Tulkens PM. Comparative activity of erythromycin and 4 new macrolides (roxithromycin, dirithromycin, rokitamycin, midecamycin) against intracellular S. aureus in J774 macrophages [abstract 157]. In: Program and abstracts of the Twenty Ninth Inter-science Conference on Antimicrobial Agents and Chemotherapy, Houston, TX. Washington, DC: American Society for Microbiology; 1989: 127.
9. Labro MT, Amit N, Babin-Chevaye C, Hakim J. Synergy between RU 28965 (roxithromycin) and human neutrophils for bactericidal activity in vitro. Antimicrob Agents Chemother 1986; 30: 137-42
10. Torigoe RK. The intracellular activity of ofloxacin and roxithromycin against Staphylococcus aureus phagocytosed in human neutrophils. Chemotherapy (Tokyo) 1993; 41: 955-62.
11. Meyer AP, Bril-Bazuin C, Mattie H, Van den Broek PJ. Uptake of azithromycin by human monocytes and enhanced intracellular antibacterial activity against Staphylococcus aureus. Antimicrob Agents Chemother 1993; 37: 2318-22.
12. Joone GK, Van Rensburg CEJ, Anderson R. Investigation of the in-vitro uptake, intraphagocytic biological activity and effects on neutrophil superoxide generation of dirithromycin compared with erythromycin. J Antimicrob Chemother 1992; 30: 509-23.
13. Anderson R, Van Rensburg CEJ, Joone G, Lukey PTJ. An in-vitro comparison of the intraphagocytic bioactivity of erythromycin and roxithromycin. J Antimicrob Chemother 1987; 20(suppl B): 57-68.
14. Kitsukawa K, Hara J, Saito AJ. Inhibition of Legionella pneumophila in guinea pig peritoneal macrophages by new quinolone, macrolide and other antimicrobial agents. J Antimicrob Chemother 1991; 27: 343-53.
15. Anderson R, Joone G, Van Rensburg CEJ. An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A 56968, TR-031), a new macrolide antimicrobial agent. J Antimicrob Chemother 1988; 22: 923-33.
16. Donowitz GR, Earnhardt KI. Azithromycin inhibition of intracellular Legionella micdadei. Antimicrob Agents Chemother 1993; 37: 2261-4.
17. Wildfeuer A, Laufen H, Muller-Wening D, Haferkamp O. Interaction of azithromycin and human phagocytic cells. Arzneim Forsch 1989; 39(11), No. 7: 755-8.
18. Stamler DA, Edelstein MA, Edelstein PH. Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila - infected and uninfected guinea pigs and their alveolar macrophages. Antimicrob Agents Chemother 1994; 38: 217-22.
19. Scaglione F, Demartini G, Dugnani S, Franchini F. A new model examining intracellular and extracellular activity of amoxicillin, azithromycin and clarithromycin in infected cells. Chemotherapy 1993; 39: 416-23.
20. Hammerschlag MT, Qumel KK, Roblin PM. In vitro activity of azithromycin, clarithromycin, L-ofloxacin and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992; 36: 1573-4.
21. Stamm WE, Sucgland R. Antimicrobial activity of U-70138F (Paldimycin), roxithromycin (RU 965), and ofloxacin (ORF 18489) against Chlamydia trachomatis in cell culture. Antimicrob Agents Chemother 1986; 30: 806-7.
22. Mentis A, Tzouvelekis LS, Tzelepi E, Iossifidou I, Karafotis F. Susceptibility of Chlamydia trachomatis isolated in Greece to erythromycin and roxithromycin [abstract 951]. Abstracts of the Eighteenth International Congress on Chemotherapy, Stockholm, 1993.
23. Orfila J, Haider F, Schmit JL, Bissac E, Bryskier A. Comparative activity of roxithromycin against Chlamydia psitacci in vitro [abstract 952]. Abstracts of the Eighteenth International Congress on Chemotherapy, Stockholm, 1993.
24. Scorneaux B, Orfila J, Tulkens PM. Activity of erythromycin and roxithromycin against Chlamydia spp. in the model of J774 macrophages in relation to their cellular accumulation [abstract 783]. Abstracts of the Seventeenth International Congress on Chemotherapy, Berlin, 1991.
25. Bermudez LE, Young LS. Activities of amikacin, roxithromycin and azithromycin alone or in combination with tumor necrosis factor against Mycobacterium avium complex. Antimicrob Agents Chemother 1988; 32: 1149-53.
26. Rastogi N, Labrousse V, Bryskier A. Intracellular activities of roxithromycin alone and in combination with other drugs against Mycobacterium avium complex in human macrophages. Antimicrob Agents Chemother 1995; 39: 976-8.
27. Yajko DM, Nassos PS, Sanders CA, Gonzalez PC, Hadley WK. Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. Antimicrob Agents Chemother 1992; 36: 1163-5.
28. Struillou L, Cohen Y, Lounis N, et al. Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice. Antimicrob Agents Chemother 1995; 39: 878-81.
29. Lazard T, Perronne C, Cohen Y, Grosset J, Vilde JL, Pocidalo JJ. Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice. Antimicrob Agents Chemother 1993; 37: 692-5.
30. Inderlied DB, Kolonovski P, Wu M, et al. In vitro and in vivo activity of azithromycin (CP67, 993) against the Mycobacterium avium complex. J Infect Dis 1989; 159: 994-7.
31. Baohong JI, Jamet P, Perani EG, Dabin P, Grosset JH. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J Infect Dis 1993; 168: 188-90.
32. Chan GP, Garcia-Ignacio BY, Chavez VE, et al. Clinical trial of clarithromycin for lepromatous leprosy. Antimicrob Agents Chemother 1994; 38: 515-17.
33. Willot I, Scorneaux B, Tulkens PM. Comparative intracellular activity of antibiotics (AB) against virulent L. monocytogenes (L.m.) and S. flexneri (S.f.) and their non-virulent mutants in a model of J774 macrophages [abstract 769]. Program and abstracts of the Thirty Third Interscience Conference. Antimicrob Agents Chemother 1993.
34. Rakita RM, Jacques-Palaz K, Murray BE. Intracellular activity of erythromycin against bacterial enteric pathogens. Antimicrob Agents Chemother 1994; 38: 1915-21.
35. Labro MT. Effect of macrolides on host natural defences. In Bryskier AJ, Butzler JP, Neu HC, Tulkens PM, eds. Macrolides: chemistry, pharmacology and clinical uses. Paris: Arnette-Blackwell, 1993: 389-408.
36. Abdelghaffar H, Mtairag EM, Labro MT. Effect of dirithromycin and erythromycylamine on human neutrophil degranulation. Antimicrob Agents Chemother 1994; 38: 1548-54.
37. Labro MT, Abdelghaffar H, Bryskier A. Effect of macrolides (M) on human neutrophil (PMN) degranulation [abstract 309]. Program and abstracts of the Thirty Third Interscience Conference. Antimicrob Agents Chemother 1993.
38. Bryskier A. Newer macrolides and their potential target organisms. Curr Opin Infect Dis 1992; 5: 764-72.
39. Bryskier A, Agouridas C, Chantot JF. New medical targets for macrolides. Exp Opin Invest Drugs 1994; 3: 405-10